SSA
SPRY icon

Schonfeld Strategic Advisors’s ARS Pharmaceuticals SPRY Stock Holding History

Schonfeld Strategic Advisors’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$165K Sell
20,546
-12,486
-38% -$107K ﹤0.01% 2228
2026
Q1 		$265K Buy
+33,032
New +$317K ﹤0.01% 1629
2024
Q3 		– Sell
-27,139
Closed -$231K – 2399
2024
Q2 		$231K Buy
+27,139
New +$241K ﹤0.01% 1768
2024
Q1 		– Sell
-16,500
Closed -$90.4K – 2384
2023
Q4 		$90.4K Buy
+16,500
New +$72.3K ﹤0.01% 1631
2022
Q4 		– Sell
-11,600
Closed -$62K – 2981
2022
Q3 		$62K Sell
11,600
-8,800
-43% -$43.4K ﹤0.01% 2613
2022
Q2 		$86K Sell
20,400
-8,100
-28% -$28.2K ﹤0.01% 2169
2022
Q1 		$100K Buy
+28,500
New +$124K ﹤0.01% 2232

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Schonfeld Strategic Advisors's SPRY Position: Q2 2026 in Review

Schonfeld Strategic Advisors reduced its ARS Pharmaceuticals (SPRY) stake by 38% in Q2 2026, selling an estimated $107K and leaving 20,546 shares worth $165K. The position accounts for ﹤0.01% of the portfolio, ranked #2228.

Schonfeld Strategic Advisors first reported a position in SPRY in Q1 2022 and has held it in 7 quarters since. The position peaked at $265K in Q1 2026. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Schonfeld Strategic Advisors held 20,546 shares of ARS Pharmaceuticals worth $165K as of Q2 2026.
  • Schonfeld Strategic Advisors sold 12,486 ARS Pharmaceuticals shares in Q2 2026, an estimated $107K.
  • ARS Pharmaceuticals made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q2 2026, its #2228 holding.
  • Schonfeld Strategic Advisors first reported a position in ARS Pharmaceuticals in Q1 2022 and has held it in 7 quarters since.
  • Schonfeld Strategic Advisors's ARS Pharmaceuticals position peaked at $265K in Q1 2026.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.